Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Precision and Ease-of-Use Characterize New Line of Microcentrifuges

By BiotechDaily International staff writers
Posted on 30 Jul 2013
Image: The Microfuge 20 micro-centrifuge (Photo courtesy of Beckman Coulter Life Sciences).
Image: The Microfuge 20 micro-centrifuge (Photo courtesy of Beckman Coulter Life Sciences).
A new line of microcentrifuges was designed to meet the specific requirements of a wide range of research applications while being efficient and easy to use.

The Beckman Coulter Life Sciences (Indianapolis, IN, USA) Microfuge 20 and 20R microcentrifuges are compact instruments that provide flexibility and reliable, precise performance whether in refrigerated (the Microfuge 20R) or nonrefrigerated (Microfuge 20) mode of operation. These microcentrifuges are intended for a wide range of biotech research applications including nucleic acid and protein preparation; pelleting, extractions, purifications, concentrations, phase separations and receptor binding; and rapid sedimentation of protein precipitates, particulates, and cell debris. An easy-to-use interface facilitates entry and recall of up to 10 user-defined programs.

Samples can be processed at speeds up to 15,000 rpm (20,627 x g) and the temperature in the Microfuge 20R can be adjusted over a range of -10 to +40 degrees Celsius. Fixed angle rotors are made of polypropylene or aluminum and offer capacities of 24 or 36 microcentrifuge tubes or four PCR tube strips.

“The Microfuge 20 series provides researchers with an accurate, reliable, and durable microcentrifuge,” said David Rolwing, centrifuge product manager at Beckman Coulter Life Sciences. “Strong performance and ergonomic features combine in these units to provide confidence and efficiency.”

Related Links:
Beckman Coulter Life Sciences




Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.